ReviewDigestive diseases and sciences2020
Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.
Review in Digestive diseases and sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Quality Upper Gastrointestinal Endoscopy in Australia and Aotearoa New Zealand: A Joint Position Statement.Journal of gastroenterology and hepatology · 2025Guideline
- Pooled it
- Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes.Scientific reports · 2025Trial
- Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects.Drugs in R&D · 2024Trial
- Nanomechanical Hallmarks ofInternational journal of molecular sciences · 2021Trial
- KPNA2 knockdown suppresses gastric cancer progression through modulation of the β-catenin/EMT signaling axis, inducing cell cycle arrest, apoptosis, and reduced metastatic capacity.Journal of molecular histology · 2026Article
- Phylogenomics-driven metalloantibiotic engineering: Overcoming ciprofloxacin resistance in Pseudomonasaeruginosa with sideromycin-bismuth synergy.Cell reports. Medicine · 2026Article
- Application value and performance of stool antigen detection in the diagnosis of Helicobacter pylori infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Current concepts of Helicobacter pylori infection.European journal of medical research · 2025Review
- The hydroalcoholic extract of the leaves of red mombin (Spondias purpurea L.) is more effective in accelerating ulcer healing than preventing them in rodents.Inflammopharmacology · 2025Article
- Risk of primary sclerosing cholangitis among patients with gastritis: a nationwide cohort study.European journal of epidemiology · 2025Article
- Article
- CRISPR/Cas9 gene editing in gastric cancer: Mechanisms, advances, and therapeutic potential.World journal of gastrointestinal pathophysiology · 2025Review
- Concordance ofMicroorganisms · 2025Article
- Research advances of the establishment and characterization ofFrontiers in microbiology · 2025Review
- Synergic Effects of Curcumin, Licorice, and Endoscopic Photodynamic Therapy Against Helicobacter Pylori by Modulating the NF-Κb Signaling Pathway.Iranian journal of biotechnology · 2025Article
- Efficacy of Sequential Metronidazole and Furazolidone with Proton Pump Inhibitors versus Standard Regimen in TreatingMedical journal of the Islamic Republic of Iran · 2025Article
- Gastroprotective Efficacy of North African Medicinal Plants: A Review on Their Therapeutic Potential for Peptic Ulcers.Food science & nutrition · 2024Review
- Factors Influencing the Degree of Gastric Atrophy inMicroorganisms · 2024Article
- Current research on the interaction between Helicobacter pylori and macrophages.Molecular biology reports · 2024Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As one of the most prevalent infections globally, Helicobacter pylori (H. pylori) continues to present diagnostic and therapeutic challenges for clinicians worldwide. Diagnostically, the "test-and-treat" strategy is the recommended approach for healthcare practitioners when managing this potentially curable disease. The choice of testing method should be based on several factors including patient age, presenting symptoms, and medication use, as well as test reliability, availability, and cost. With rising antibiotic resistance, particularly of macrolides, care must be taken to ensure that therapy is selected based on regional resistance patterns and prior antibiotic exposure. In the USA, macrolide antibiotic resistance rates in some areas have reached or exceeded a generally accepted threshold, such that clarithromycin triple therapy may no longer be an appropriate first-line empiric treatment. Instead, bismuth quadruple therapy should be considered, while levofloxacin-based or alternative macrolide-containing therapies are also options. Once treated, it is essential to test for eradication as untreated H. pylori is associated with serious complications including peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. This review article aims to consolidate current knowledge of H. pylori infection with a particular emphasis on diagnostic and treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.